Foley JF - Search Results

1

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.

Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.

2

Monoclonal antibody treatments for multiple sclerosis.

Rose JW, Foley J, Carlson N. Rose JW, et al. Curr Neurol Neurosci Rep. 2008 Sep;8(5):419-26. doi: 10.1007/s11910-008-0065-3. Curr Neurol Neurosci Rep. 2008. PMID: 18713579 Review.

3

Redefining functionality and treatment efficacy in multiple sclerosis.

Foley JF, Brandes DW. Foley JF, et al. Neurology. 2009 Jun 9;72(23 Suppl 5):S1-11. doi: 10.1212/WNL.0b013e3181a99bc2. Neurology. 2009. PMID: 19506262

4

Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.

Foley J. Foley J. Am J Manag Care. 2010 Jun;16(6 Suppl):S178-83. Am J Manag Care. 2010. PMID: 20615054 Free article.

5

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.

Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, Bozic C, Richman S. Vermersch P, et al. Among authors: foley jf. Neurology. 2011 May 17;76(20):1697-704. doi: 10.1212/WNL.0b013e31821a446b. Neurology. 2011. PMID: 21576685

6

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.

7

Emerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis.

Foley JF, Barnes CJ, Nair KV. Foley JF, et al. J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S16-23. doi: 10.18553/jmcp.2013.19.s1.S16. J Manag Care Pharm. 2013. PMID: 23383728 Free PMC article. Review.

8

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765

9

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P; RESTORE. Fox RJ, et al. Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28. Neurology. 2014. PMID: 24682966 Free PMC article. Clinical Trial.

10

The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study.

Khatri BO, Foley JF, Fink J, Kramer JF, Cha C, You X, Warth JD, Foulds P. Khatri BO, et al. Among authors: foley jf. Int J MS Care. 2014 Spring;16(1):40-7. doi: 10.7224/1537-2073.2013-003. Int J MS Care. 2014. PMID: 24688353 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

271 results

Search Page